Statins: The Hmg Coa Reductase Inhibitors in Perspective

ISBN-13: 9781841842929 / Angielski / Twarda / 2003 / 272 str.

Chris Allan Gaw; Allan Gaw; Chris Packard

Opis

Statins are the most powerful lipid-lowering agent yet produced. Their main action is to lower the low-density lipoprotein (LDL) cholesterol level, thereby reducing the overall cholesterol level in the blood. In the new edition of this popular book, the authors examine the existing and emerging statins and their beneficial effectiveness in reducing serum cholesterol. New chapters cover combination therapy in lipid-lowering, new 'Megatrials' (HPS and PPP) and the PROSPER study and the effects of statins on non-vascular conditions such as osteoporosis, cancer, dementia and diabetes.

Spis treści

1. Hyperlipidaemia as a Risk Factor for Coronary Heart Disease 2. Lipid Control in the Pre-Statin Era 3. The Discovery and Development of the Statins 4. Comparative Chemistry, Pharmacology and the Mechanism of Action of the Statins 5. Ancillary Benefits of the Statins 6. Angiographic and IVUS Techniques Evaluating Progression and Regression of Coronary Atherosclerosis: Statin Intervention Trials in Perspective 7. The Scandanavian Simvastatin Survival Study (4S) 8. Primary Prevention of Coronary Heart Disease with Statins 9. The CARE (Cholesterol and Recurrent Events) Trial: The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels 10. The LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) Study: Results and Implications for Clinical Practice 11. Mega-trials: the Prospective Pravastatin Pooling Project (PPP) and the Heart Protection Study (HPS) 12. The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 13. Combination Therapy with Statins 14. Guidelines for Clinical Use of the Statins 15. The Cost-effectiveness of Statin Use 16. Unanswered Questions About the Use of Statins 17. Statin Therapy for the 21st Century